Why Are Doctors Hesitant to Prescribe Naltrexone?

Naltrexone has been FDA-approved for alcohol use disorder since 1994 and has over 20,000 patients worth of clinical trial data behind it. Most people who could benefit from it never receive a prescription. Understanding why helps you advocate for yourself.

What You'll Discover:

• Why naltrexone is so rarely prescribed despite strong evidence.

• The specific reasons doctors are hesitant, and how well-founded those reasons are.

• Common misconceptions about naltrexone that persist in medical training.

• What has changed in recent years that is improving access.

• How to get naltrexone if your doctor has been reluctant to prescribe it.

There is a significant gap between what medical research shows and what happens in a doctor's office. Naltrexone is one of the clearest examples of that gap. It is FDA-approved, has decades of clinical evidence, and is recommended by the NIAAA, the American Society of Addiction Medicine, and the Substance Abuse and Mental Health Services Administration. And yet, estimates suggest that fewer than 5% of people with alcohol use disorder ever receive medication-assisted treatment of any kind.

The reasons for this gap are not simple. They involve physician training, medical culture, longstanding stigma, and some specific misconceptions about naltrexone that have proven surprisingly durable. Understanding them matters, because knowing they exist makes it easier to work around them.

The Scale of the Treatment Gap

Before getting into the reasons, it is worth appreciating the scale of the problem. Alcohol use disorder affects approximately 29 million Americans, according to the National Institute on Alcohol Abuse and Alcoholism. Effective pharmacological treatments exist. A 2023 meta-analysis covering 118 clinical trials and over 20,000 participants confirmed naltrexone as one of the most evidence-supported first-line options available.

Despite this, the majority of people with alcohol use disorder receive no medication at all. Of those who do seek treatment, the number who are offered naltrexone specifically is a small fraction. This is not a supply problem or an access problem in most cases. It is a prescribing problem.

Reason 1: Inadequate Training in Medical School and Residency

The most fundamental reason is that most physicians simply were not trained to prescribe medications for alcohol use disorder. Historically, medical school curricula devoted very little time to addiction medicine. A survey often cited in the addiction medicine literature found that U.S. medical schools devoted an average of fewer than ten hours of training to substance use disorders across four years of education.

When physicians complete training without exposure to naltrexone prescribing, it does not naturally appear in their clinical toolkit. Prescribing a medication you were never taught to use, for a condition you received minimal training on, is not something most physicians do spontaneously. The result is that naltrexone sits in the drug formulary, FDA-approved and evidenced, while physicians defaultly refer patients to behavioral programs that may or may not include medication.

Reason 2: The Abstinence-First Misconception

A significant number of physicians learned that patients with alcohol use disorder should achieve abstinence before starting any medication. This idea, while well-intentioned, misunderstands how naltrexone works and has been contradicted by clinical evidence for decades.

Naltrexone is most effective when taken before or during drinking. Its mechanism involves blocking the opioid receptors that produce the rewarding effects of alcohol. That mechanism requires alcohol to be present in order to do its work. Requiring abstinence before prescribing naltrexone is like requiring someone to stop bleeding before applying a bandage.

The National Institutes of Health StatPearls database is explicit on this point: naltrexone can be started while patients are still actively drinking. The evidence supports this approach. Yet the abstinence-first expectation persists in clinical practice, leading physicians to withhold the medication or patients to feel they need to earn it.

Reason 3: Exaggerated Concern About Liver Toxicity

Naltrexone is metabolized by the liver. Some physicians are reluctant to prescribe it to patients who drink heavily because they worry it will further damage a liver that is already under strain from alcohol.

This concern is legitimate in a specific and narrow sense: naltrexone at very high doses (300mg daily) has been associated with hepatotoxicity in clinical testing. At the standard therapeutic dose of 50mg per day, the clinical evidence does not support hepatotoxicity as a significant risk in patients without severe pre-existing liver disease.

The StatPearls reference notes that naltrexone should be used with caution in patients with active hepatitis or liver failure, and should be avoided entirely in patients with severe hepatic impairment. But for the large majority of people with alcohol use disorder who have mild to moderate liver changes from drinking, naltrexone at standard doses is considered safe. The liver damage risk from continued heavy drinking far exceeds the theoretical liver risk from naltrexone.

The practical effect of overstating the liver risk is that the patients who most need naltrexone are the ones most likely to be told they cannot have it.

Reason 4: Stigma Around Addiction Medicine

Addiction medicine carries stigma in both directions. Patients with alcohol use disorder are sometimes perceived through a moral rather than medical lens, which can affect the level of engagement and treatment sophistication they receive. And prescribing medications for addiction can carry its own stigma for physicians, a residual association with enabling or substituting one substance for another.

This is not uniform across physicians or practice settings. Addiction medicine specialists and many primary care physicians who have invested in this area are excellent prescribers. But for generalists, internists, and others who encounter patients with alcohol use disorder incidentally, the stigma-influenced hesitancy is real.

The framing of alcohol use disorder as a medical condition with neurobiological roots, rather than a moral failure, has been growing in medicine as in the broader culture. But culture changes slowly, and the effects are not yet uniformly distributed across clinical practice.

Reason 5: The Time and Complexity Problem

A primary care appointment is typically 15 to 20 minutes. Initiating naltrexone treatment requires screening for contraindications, discussing the mechanism and expectations, addressing questions about side effects, arranging monitoring, and following up. For a physician with a full panel of patients and limited time, it is easier to refer to a specialist or a behavioral program than to take on a new and somewhat unfamiliar prescribing pathway.

This is not a criticism of individual physicians. It is a systems problem. The structure of primary care in the United States is not well-designed for managing chronic conditions that require time and nuance. Alcohol use disorder, like other addiction conditions, often falls into the gap.

What Has Changed: Telehealth and Specialized Access

The picture has been improving, particularly since telehealth expanded significantly. Platforms that specialize in alcohol use treatment can prescribe naltrexone through an online consultation, often within 24 hours. The barriers of geographic access, appointment availability, and primary care reluctance can be bypassed entirely.

The NIAAA recommends that people seeking help for alcohol use disorder ask their doctor directly about medications, and notes that naltrexone is an FDA-approved option that more patients should be offered. Knowing that the medication exists and that you can ask for it by name shifts the dynamic considerably.

Our article on naltrexone online covers how the telehealth prescribing pathway works and what to expect. And for those wondering whether the online approach is legitimate, our piece on why online naltrexone should assist therapists not replace them addresses the clinical and practical context.

What This Means for You

If you have spoken to a doctor about alcohol use and were not offered naltrexone, you are not unusual. The treatment gap is large and well-documented. But the medication is available, the evidence is strong, and access has improved meaningfully.

You can ask your doctor about naltrexone specifically. You can ask whether there are any reasons it would not be appropriate for you, and if so, what they are. Many physicians will prescribe it when asked directly, even if they would not have raised it unprompted.

You can also access it through a specialized telehealth service without going through your primary care physician at all. The consultation is typically message-based, takes place the same day, and naltrexone can arrive within a few days. Understanding how naltrexone works before that conversation helps you ask better questions and know what to expect.

The treatment gap is a systemic problem, but its effects on individuals are not fixed. You do not have to wait for the system to improve before getting access to a medication that has been available for thirty years.

To take the first step, you can complete an online Alcohol Use Assessment and see whether naltrexone could be a good fit for your situation. It is discreet, takes a few minutes, and puts you in touch with a clinician who specializes in exactly this.